The story of Sildenafil presents a interesting case for investors in the drug sector. While initially a tremendous success, generating vast sums, the intellectual property lapse and the subsequent entry of cheaper versions have significantly affected earnings. This poses questions about the ongoing profitability of similar therapeutic developmen… Read More